|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||14.25 - 14.25|
|52 Week Range||12.15 - 19.50|
|Beta (5Y Monthly)||0.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.26 (1.85%)|
|Ex-Dividend Date||Mar 30, 2020|
|1y Target Est||N/A|
The U.S. Food and Drug Administration on Thursday approved a sublingual film from Sunovion Pharmaceuticals Inc, a unit of Japan-based Sumitomo Dainippon , for the treatment of "off" episodes in patients with Parkinson's disease, according to a label published by the agency. Parkinson's disease is a nervous system disorder in which patients suffer from motor fluctuations which oscillate between "off" times, a state of decreased mobility, and "on" times, or periods when the medication is working and symptoms are controlled.
Japan's Sumitomo Dainippon Pharma Co will pay $3 billion for a 10% stake in Swiss drugmaker Roivant Sciences Ltd and interests in five of its biopharmaceutical businesses, the two companies said on Friday. The deal, which will open up new drug lines for Sumitomo Dainippon, will also give it the option to acquire interests in an additional six businesses, as well as access to Roivant's technology platforms, they said in a statement. It comes as Sumitomo Dainippon's schizophrenia treatment Latuda is due to lose its U.S. market exclusivity in 2023.